Company Overview
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Why Investors Should Care
Revenue has grown at a 74.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $134.48M (-3.9% YoY); net profit $-38.94M.
- Trailing 12 Months Year-on-year growth — revenue +0.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 74.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 73.98% |
| 1 Year: | 0.30% |
Stock Price Performance
| 1 Year: | -39.59% |
| 6 Months: | -30.76% |
| 3 Months: | -10.99% |
| 1 Month: | +6.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.90 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 74.0% over 5 years.
CONS
- Trading 61.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RXST RxSight, Inc. R2KR3KPHARMA | 5.02 | -4.40 | $208.80M | 0.00% | -16.88% | -17.34% | 73.98% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.71M | 4.17M | 3.48M | 4.90M | 5.79M | 8.94M | 11.36M | 12.62M | 17.49M | 20.81M | 22.20M | 29.51M | 34.89M | - | - | 37.90M | 33.64M | 30.34M | 32.61M | 30.89M | 27.24M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.57M | 8.45M | 6.11M | 7.34M | 7.39M | - |
| Gross Profit | - | -474.00K | 720.00K | 1.12M | -812.00K | 1.34M | 3.76M | 4.79M | 5.36M | 10.37M | 12.02M | 13.73M | 20.68M | 24.25M | - | - | 28.33M | 25.19M | 24.23M | 25.26M | 23.50M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.00M | 39.19M | 36.41M | 36.60M | 41.33M | - |
| Operating Income | - | -8.81M | -8.91M | -11.13M | -13.88M | -13.11M | -16.58M | -15.79M | -15.96M | -13.10M | -13.62M | -12.51M | -10.67M | -8.33M | - | - | -10.67M | -14.00M | -12.18M | -11.34M | -17.83M | -13.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.38M | -10.97M | -8.95M | -8.29M | -15.04M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.00K | 5.00K | 4.00K | 5.00K | 3.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.17M | -11.75M | -9.81M | -9.15M | -15.88M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 32.00K | 10.00K | 5.00K | 6.00K | - |
| Net Income | -16.50M | -12.88M | 30.66M | -6.80M | -13.48M | -12.67M | -17.60M | -16.73M | -16.82M | -13.21M | -13.80M | -12.41M | -9.10M | -6.08M | - | - | -8.19M | -11.79M | -9.82M | -9.15M | -15.88M | -12.10M |
| Diluted EPS | - | 0.00 | 0.00 | - | -3.53 | -0.68 | -0.64 | -0.61 | -0.61 | -0.42 | -0.40 | -0.35 | -0.25 | -0.16 | - | - | -0.20 | -0.29 | -0.24 | -0.22 | -0.38 | -0.29 |
| R&D Expense | - | 5.08M | 5.80M | 6.64M | 6.56M | 5.38M | 6.72M | 6.19M | 6.39M | 7.21M | 7.40M | 7.10M | 8.03M | 8.29M | 8.84M | - | 10.37M | 10.22M | 9.06M | - | 9.47M | 9.24M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 14.68M | - | 49.01M | 89.08M | 139.93M | 134.48M |
| Cost of Revenue | - | - | 27.68M | 35.31M | 40.98M | 31.47M |
| Gross Profit | 1.71M | - | 21.33M | 53.77M | 98.94M | 103.01M |
| Operating Expenses | - | - | 84.65M | 103.85M | 135.80M | 151.20M |
| Operating Income | -35.41M | - | -63.32M | -50.09M | -36.86M | -48.19M |
| EBITDA | - | - | -57.78M | -41.20M | -23.81M | -35.59M |
| Interest Expense | - | - | 4.95M | 3.31M | 21.00K | 19.00K |
| Pretax Income | - | - | -66.75M | -48.59M | -27.41M | -38.88M |
| Tax Provision | - | - | 9.00K | 20.00K | 50.00K | 66.00K |
| Net Income | 27.57M | - | -66.76M | -48.61M | -27.45M | -38.94M |
| Diluted EPS | 0.15 | - | -2.41 | -1.41 | -0.71 | -0.95 |
| R&D Expense | 21.93M | 24.50M | 25.98M | 29.05M | 34.37M | 38.55M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 100.68M | - | 150.16M | 182.55M | 318.56M | 311.81M |
| Current Assets | - | - | - | 134.56M | 168.41M | 293.82M | 287.46M |
| Cash & Equivalents | - | 13.99M | - | 11.83M | 9.69M | 16.71M | 19.95M |
| Inventory | - | - | - | 14.84M | 17.42M | 22.01M | 31.56M |
| Receivables | - | - | - | 10.96M | 20.28M | 30.05M | 23.38M |
| Total Liabilities | - | 44.91M | - | 60.26M | 22.19M | 37.33M | 36.13M |
| Current Liabilities | - | 11.60M | - | 17.24M | 20.90M | 25.88M | 26.25M |
| Long Term Debt | - | 24.40M | 39.76M | 40.17M | - | - | - |
| Total Debt | - | - | - | 44.99M | 3.01M | 12.30M | 11.04M |
| Total Equity | -419.81M | -430.59M | - | 89.90M | 160.36M | 281.24M | 275.68M |
| Shares Outstanding | - | - | - | 28.27M | 36.14M | 40.43M | 41.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.20M | -44.71M | -58.85M | -41.59M | -16.95M | -15.51M |
| Investing Cash Flow | 15.59M | -81.91M | 39.95M | -22.13M | -99.31M | 16.89M |
| Financing Cash Flow | 25.24M | 137.34M | 6.33M | 61.52M | 123.32M | 1.86M |
| Capital Expenditure | -2.54M | -1.94M | -2.39M | -4.81M | -5.44M | -3.83M |
| Free Cash Flow | -37.74M | -46.65M | -61.24M | -46.41M | -22.39M | -19.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 11.6% | - | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating Margin % | -241.3% | - | -129.2% | -56.2% | -26.3% | -35.8% |
| Net Margin % | 187.9% | - | -136.2% | -54.6% | -19.6% | -29.0% |
| ROE % | -6.4% | - | -74.3% | -30.3% | -9.8% | -14.1% |
| ROCE % | -39.8% | - | -47.6% | -31.0% | -12.6% | -16.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.92% | 5.79M | $27.85M |
| 2 | Millennium Management Llc | 7.29% | 3.03M | $14.58M |
| 3 | No Street GP LP | 4.94% | 2.06M | $9.88M |
| 4 | Nomura Holdings Inc. | 4.81% | 2.00M | $9.62M |
| 5 | Shaw D.E. & Co., Inc. | 4.77% | 1.99M | $9.55M |
| 6 | Vanguard Capital Management LLC | 4.03% | 1.68M | $8.06M |
| 7 | AQR Capital Management, LLC | 3.69% | 1.53M | $7.38M |
| 8 | Acadian Asset Management. LLC | 3.61% | 1.50M | $7.22M |
| 9 | Federated Hermes, Inc. | 2.89% | 1.20M | $5.78M |
| 10 | Two Sigma Investments, LP | 2.76% | 1.15M | $5.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RXST
RxSight, Inc. (RXST) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE12SmxBc210eTFXNF9fTDJVLTFHRXkyeTZzTEJtazdzVTk2ME9MM1UzeG1neWNVRkx3SElyTm5WLTBiQWNHR2JuVlBOX3Y3c3FhQVE?oc=5" target="_blank">RxSight, Inc. (RXST) Stock Price, News, Quote & History<…
RxSight(RXST) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMi2AJBVV95cUxQWEY5RW5tQms4NFlhdjl1X3Z0SXdRd2x1b1MyS0YxRDF1WWdLU0tNbFRubUd0VldoOHBGeEQ0WmZSVklmak5lLWFFLXJrSzN3bWRmUVFFVl9XYk43VXpTdXpCRGg0QjlUTVRvV2xNRHFGOFB4cFZtb0ZEVTRuYjd6bk01NGtOMWRvMTVBMU…
A sales leader with over 30 years in eye care joins RxSight. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQYUp2UGEzeTdkT2VzYmg2empTM2hiQWRjeFBDQ3I0S094VEVpTl9zaXZfaVJMVUF1bHpZUWZ5Nm9ISUZpZUpGeGJrT3dXdWRpR2RvMmswSDQtYjFGVWFzOUlTREZwOFdQVjA5RzJYbE5XQkQwaHB1cHB5aHg5RVhfemN3LUpiQzRBOGZRMX…
RXST Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9EakRxWUVlUzRnVGJGOVdLX0xPODdPTV9yZURhLVVKaHhFZWtmQnh6Tk9jd09IcmVmTG1vUmFHRXRDZkVjWjJEaGF6Tk1tN3RoM0piLTNTQnY1aUJYQ2FXd1pBVE0wenBDNF9WMFJvTlFmX3pwTHlJSjhB?oc=5" target="_blank">RXS…
RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOV1lleHppYUdpRFpjRS1VV3EzenM2UVF1QkFmUzdEaUItZ2NfbFJ2NXhOT3dYNUFIa0V1TkpZLTI1VEZZVFRzY21PekgtLU80U1BjZFFRYWZxSlZ6YWpQTE1zQURGSjhJNkVTRWwxaUszdEwtWWFGLVlwNkxOZ1BPMDRYcUh5Sk95MXU4Uk…
RxSight (RXST) Stock Faces Margin Strain After Guidance Withdrawal - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPeHp1bzNaS3U5SHQybGNsNW1Tbkl2MVFTVnZtQVVsU1VpVVZMWDZIWC1DZ1RaYkpfTWhReGNkQkhnNjE0LUNFOEcydEpHYmwwQldsa28wbnlvWjZmeXQta3hGRUQzbmhUOTBEeFJ2bTZRMTNBdjN6b0FmVEY3UXZHRmZ3WWhTSWFCcWlrNV…
RXST — Frequently Asked Questions
What is the current share price of RxSight, Inc. (RXST)?
As of 2026-10-23 16:27 PDT, RxSight, Inc. (RXST) trades at $5.02 on NasdaqGM. Its 52-week range is $4.51 to $13.09.
What is the market capitalisation of RXST?
RxSight, Inc. (RXST) has a market capitalisation of $208.80M on NasdaqGM.
What is the P/E ratio of RXST?
RXST trades at a trailing price-to-earnings (P/E) ratio of -4.40. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.82.
What is the return on equity (ROE) of RXST?
RXST has a return on equity (ROE) of -17.34%. Its return on capital employed (ROCE) is -16.88%.
Is RXST a good stock to buy?
This page provides a data-driven analysis of RxSight, Inc. (RXST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.